UPB
Upstream Bio, Inc. Common StockUPB
UPB
About: Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.
–
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$38
134%
upside
Avg. target
$57
249%
upside
High target
$75
363%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
JP Morgan Tessa Romero 22% 1-year accuracy 4 / 18 met price target | 134%upside $38 | Overweight Initiated | 5 Nov 2024 |
Piper Sandler Yasmeen Rahimi 48% 1-year accuracy 14 / 29 met price target | 363%upside $75 | Overweight Initiated | 5 Nov 2024 |
Financial journalist opinion
Neutral
Seeking Alpha
6 days ago
Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation
Upstream Bio, Inc. raised approximately $293 million in an IPO, positioning it to leverage upstream pathway targeting of TSLP for treatment of patients with respiratory disorders using verekitug. Release of results from the phase 2 study, using verekitug for the treatment of patients with Chronic Rhinosinusitis with Nasal Polyps, expected to be released in the 2nd half of 2025. The global Chronic Rhinosinusitis market is expected to reach $3.5 billion by 2027.
Neutral
GlobeNewsWire
1 week ago
Upstream Bio Announces Addition to Russell 2000® Index
WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company will be added to the Russell 2000® index as part of the planned fourth quarter initial public offering (IPO) additions effective at the open of the U.S. equity markets on December 23, 2024.
Positive
MarketBeat
1 month ago
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical companies.
Positive
Benzinga
1 month ago
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Just two weeks ago, Upstream Bio, Inc. UPB closed its upsized initial public offering (IPO) of 17.25 million shares at $17 per share, with gross proceeds of approximately $293 million.
Neutral
GlobeNewsWire
2 months ago
Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the closing of its upsized initial public offering of 17,250,000 shares of its common stock at a public offering price of $17.00 per share, which includes 2,250,000 shares issued upon the full exercise by the underwriters of their option to purchase additional shares of common stock.
Positive
Reuters
2 months ago
Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut
Shares of Upstream Bio opened 26.5% above the initial public offering price in their Nasdaq debut on Friday, valuing the drug developer at $1.05 billion.
Positive
Reuters
2 months ago
Upstream Bio raises $255 mln in US IPO
Upstream Bio , which is developing treatments for some respiratory disorders, said on Thursday it had raised $255 million in its initial public offering in the United States.
Neutral
GlobeNewsWire
2 months ago
Upstream Bio Announces Pricing of Upsized Initial Public Offering
WALTHAM, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the pricing of its upsized initial public offering of 15,000,000 shares of its common stock at a public offering price of $17.00 per share.
Charts implemented using Lightweight Charts™